A
Amy E. Cyr
Researcher at Washington University in St. Louis
Publications - 50
Citations - 3595
Amy E. Cyr is an academic researcher from Washington University in St. Louis. The author has contributed to research in topics: Breast cancer & Mastectomy. The author has an hindex of 16, co-authored 49 publications receiving 3190 citations.
Papers
More filters
Journal ArticleDOI
Clinical practice guidelines in oncology
William J. Gradishar,Benjamin O. Anderson,Ron Balassanian,Sarah L. Blair,Harold J. Burstein,Amy E. Cyr,Anthony D. Elias,William B. Farrar,Andres Forero,Sharon H. Giordano,Matthew P. Goetz,Lori J. Goldstein,Steven J. Isakoff,Janice A. Lyons,P. Kelly Marcom,Ingrid A. Mayer,Beryl McCormick,Meena S. Moran,Ruth O'Regan,Sameer A. Patel,Lori J. Pierce,Elizabeth C. Reed,Kilian E. Salerno,Lee S. Schwartzberg,Amy Sitapati,Karen L. Smith,Mary Lou Smith,Hatem Soliman,George Somlo,Melinda L. Telli,John H. Ward,Rashmi Kumar,Dorothy A. Shead +32 more
TL;DR: This manuscript focuses on the NCCN Guidelines Panel recommendations for the workup, primary treatment, risk reduction strategies, and surveillance specific to DCIS.
Journal ArticleDOI
Invasive breast cancer version 1.2016
William J. Gradishar,Benjamin O. Anderson,Ronald Balassanian,Sarah L. Blair,Harold J. Burstein,Amy E. Cyr,Anthony D. Elias,William B. Farrar,Andres Forero,Sharon H. Giordano,Matthew P. Goetz,Lori J. Goldstein,Clifford A. Hudis,Steven J. Isakoff,P. Kelly Marcom,IA Mayer,Beryl McCormick,Meena S. Moran,Sameer A. Patel,Lori J. Pierce,Elizabeth C. Reed,Kilian E. Salerno,Lee S. Schwartzberg,Karen L. Smith,Mary Lou Smith,Hatem Soliman,George Somlo,Melinda L. Telli,John H. Ward,Dorothy A. Shead,Rashmi Kumar +30 more
TL;DR: The NCCN Guidelines specific to breast cancer that is locoregional (restricted to one region of the body) are outlined, and the management of clinical stage I, II, and IIIA (T3N1M0) tumors are discussed.
Journal ArticleDOI
NCCN Guidelines® insights breast cancer, version 1.2017: Featured updates to the NCCN Guidelines
William J. Gradishar,Benjamin O. Anderson,Ronald Balassanian,Sarah L. Blair,Harold J. Burstein,Amy E. Cyr,Anthony D. Elias,William B. Farrar,Andres Forero,Sharon H. Giordano,Matthew P. Goetz,Lori J. Goldstein,Steven J. Isakoff,Janice A. Lyons,P. Kelly Marcom,Ingrid A. Mayer,Beryl McCormick,Meena S. Moran,Ruth M. O'Regan,Sameer A. Patel,Lori J. Pierce,Elizabeth C. Reed,Kilian E. Salerno,Lee S. Schwartzberg,Amy M. Sitapati,Karen L. Smith,Mary Lou Smith,Hatem Soliman,George Somlo,Melinda L. Telli,John H. Ward,Dorothy A. Shead,Rashmi Kumar +32 more
TL;DR: This report summarizes the important updates/changes to the surgical axillary staging, radiation therapy, and systemic therapy recommendations for hormone receptor-positive disease in the 1.2017 version of the NCCN Guidelines for Breast Cancer and discusses the rationale behind them.
Journal ArticleDOI
Breast cancer, version 1.2016 featured updates to the NCCN guidelines
William J. Gradishar,Benjamin O. Anderson,Ronald Balassanian,Sarah L. Blair,Harold J. Burstein,Amy E. Cyr,Anthony D. Elias,William B. Farrar,Andres Forero,Sharon H. Giordano,Matthew Bidwell Goetz,Lori J. Goldstein,Clifford A. Hudis,Steven J. Isakoff,P. Kelly Marcom,Ingrid A. Mayer,Beryl McCormick,Meena S. Moran,Sameer A. Patel,Lori J. Pierce,Elizabeth C. Reed,Kilian E. Salerno,Lee S. Schwartzberg,Karen L. Smith,Mary Lou Smith,Hatem Soliman,George Somlo,Melinda L. Telli,John H. Ward,Dottie A. Shead,Rashmi Kumar +30 more
TL;DR: In the most recent version of these guidelines, the NCCN Breast Cancer Panel included a new section on the principles of preoperative systemic therapy, and based on new evidence, the panel updated systemic therapy recommendations for women with hormone receptor-positive breast cancer in the adjuvant and metastatic disease settings and for patients with HER2-positive metastatic breast cancer as discussed by the authors.
Journal ArticleDOI
NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer.
Cynthia X. Ma,Feng Gao,Jingqin Luo,Donald W. Northfelt,Matthew P. Goetz,Andres Forero,Jeremy Hoog,Michael Naughton,Foluso O. Ademuyiwa,Rama Suresh,Karen S. Anderson,Julie A. Margenthaler,Rebecca Aft,Timothy J. Hobday,Timothy J. Moynihan,William E. Gillanders,Amy E. Cyr,Timothy J. Eberlein,Tina J. Hieken,Helen Krontiras,Zhanfang Guo,Michelle V. Lee,Nicholas C. Spies,Zachary L. Skidmore,Obi L. Griffith,Malachi Griffith,Shana Thomas,Caroline Bumb,Kiran Vij,Cynthia Huang Bartlett,Maria Koehler,Hussam Al-Kateb,Souzan Sanati,Matthew J. Ellis +33 more
TL;DR: Palbociclib is an active antiproliferative agent for early-stage breast cancer resistant to anastrozole; however, prolonged administration may be necessary to maintain its effect.